Retroperitoneal Sarcomas: Histology Is Everything

Michael K Turgeon; Kenneth Cardona

doi:10.1016/j.suc.2022.04.004

Retroperitoneal Sarcomas: Histology Is Everything

Surg Clin North Am. 2022 Aug;102(4):601-614. doi: 10.1016/j.suc.2022.04.004.

Authors

Michael K Turgeon¹, Kenneth Cardona²

Affiliations

¹ Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE, Building B, Suite 4100, Office 4201, Atlanta, GA 30322, USA.
² Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, 550 Peachtree Street, NE, 9th Floor, Suite 900, Atlanta, GA 30308, USA. Electronic address: ken.cardona@emory.edu.

PMID: 35952690
DOI: 10.1016/j.suc.2022.04.004

Abstract

Retroperitoneal sarcomas (RPS) are a rare subset of soft tissue sarcoma that are composed of only a few histologic subtypes, each with a distinct tumor biology, clinical presentation, preferred treatment strategy, recurrence risk, and surveillance plan. In the modern era of precision medicine, our understanding of the implications of subtype tumor biology and anatomic location has led to a more nuanced, histology-specific approach to therapy, including surgery, neoadjuvant radiation therapy, and/or chemotherapy. This article provides a summary of recent updates to the management of RPS.

Keywords: Active surveillance; Histiotype; Multimodality therapy; Retroperitoneal sarcoma; Surgery.

Publication types

Review

MeSH terms

Humans
Neoadjuvant Therapy
Retroperitoneal Neoplasms* / pathology
Sarcoma* / diagnosis
Sarcoma* / pathology
Sarcoma* / therapy
Soft Tissue Neoplasms* / pathology